Skip to content

Gender-related Characteristics of Bladder Cancer Treatment

Gender-related Characteristics of Bladder Cancer Treatment. Therapeutic Offer, Pathologic Features and Survival Outcomes of Patients Treated With Radical Cystectomy for Muscle-invasive Bladder Cancer

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04687254
Acronym
BladderBLOG
Enrollment
500
Registered
2020-12-29
Start date
2020-09-01
Completion date
2021-06-30
Last updated
2020-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer, Muscle-invasive Bladder Cancer, Radical Cystectomy

Brief summary

The most frequent cancer of the urinary tract is the bladder cancer (BC), in Italy its incidence reaches the 7% of all the new diagnosis of cancer, accounting for the fifth cause of death in the western countries, overall 140.000 new cases per year in Europe. In the year 2017, the Italian association for medical oncology (AIOM) recorded in our country about 21.700 new diagnosis of BC men and 5.300 in women. This data show not only a relevant gender disparity on the disease incidence (in 5th to 7th decade male incidence: 11-12% of all new diagnosis of cancer versus 1% in women) but also on the outcomes of treatment. Overall, the 30% of all the new diagnosis have a muscle-invasive (MIBC) onset, the female gender suffer a correlation with a more advanced disease at the time of first diagnosis. As a consequence, men have lower BC-related mortality when compared to women (p\<0,001). This discrepancy in the mortality rate has been investigated by many authors, resulting in the evidence that female gender suffers higher risks, especially during the first two-years after the radical cystectomy. A comprehensive explanation has not been formulated yet, but a multiplicity of cofactors, including variations in the hormone receptors and tumor biology as well as the different anatomy between male and female, have been identified as potentially relevant. Another important issue in the pre-operatory management of female patients with BC is the misleading interpretation of hematuria. It seems to directly correlate with the evidence that women suffer a more advanced stage at diagnosis, and this element has been withheld in the list of relevant risk factors for prognosis. Nevertheless, a thorough analysis of their effect will only be possible in the future, as well-designed prospective and randomized clinical trials are currently not available. A part from the preoperatory disparity, it has also been described that men are more frequently candidates to an orthotopic urinary diversion, leading female patients to an irreversibly altered perception of personal integrity and body image, namely to a lower quality of life after radical cystectomy. The female anatomy has been considered as a limitation to continence recovery, resulting in preoperative counselling more frequently against in favor of ileal conduit or not-continent urinary diversions.

Interventions

None listed

Sponsors

marco Carini
CollaboratorUNKNOWN
Sergio Serni
CollaboratorUNKNOWN
Andrea Minervini
CollaboratorUNKNOWN
Pietro Spatafora
CollaboratorUNKNOWN
Giandomenico Roviello
CollaboratorUNKNOWN
Gabriella Nesi
CollaboratorUNKNOWN
Ilaria Camilla Galli
CollaboratorUNKNOWN
Calogero Saieva
CollaboratorUNKNOWN
Graziano Vignolini
CollaboratorUNKNOWN
Giovani Tasso
CollaboratorUNKNOWN
Simone Morselli
CollaboratorUNKNOWN
University of Florence
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Patient undergoing radical cystectomy since September 2016 December 2020 * Development of bladder cancer confirmed histologically * Written informed consent

Exclusion criteria

• Lack of clinical and prognostic data on selected patients

Design outcomes

Primary

MeasureTime frame
gender-related discrepancies in the treatment offer for patients affected by MIBC from September 2016 to December 202036 months

Secondary

MeasureTime frame
gender-related difference in the clinical and pathologic features of MIBC36 months
gender-related difference in the survival outcomes36 months
gender-related difference in the risk factors for development of BC36 months

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026